Bank of America Corp DE increased its stake in Loxo Oncology, Inc. (NASDAQ:LOXO) by 162.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 8,176 shares of the biopharmaceutical company’s stock after buying an additional 5,063 shares during the period. Bank of America Corp DE’s holdings in Loxo Oncology were worth $344,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the company. Teachers Advisors LLC increased its stake in Loxo Oncology by 4.3% in the fourth quarter. Teachers Advisors LLC now owns 22,139 shares of the biopharmaceutical company’s stock valued at $711,000 after buying an additional 905 shares during the period. Nationwide Fund Advisors increased its stake in Loxo Oncology by 31.9% in the first quarter. Nationwide Fund Advisors now owns 27,434 shares of the biopharmaceutical company’s stock valued at $1,154,000 after buying an additional 6,632 shares during the period. Wells Fargo & Company MN increased its stake in Loxo Oncology by 33.3% in the first quarter. Wells Fargo & Company MN now owns 15,503 shares of the biopharmaceutical company’s stock valued at $653,000 after buying an additional 3,875 shares during the period. DekaBank Deutsche Girozentrale increased its stake in Loxo Oncology by 92.0% in the first quarter. DekaBank Deutsche Girozentrale now owns 19,200 shares of the biopharmaceutical company’s stock valued at $803,000 after buying an additional 9,200 shares during the period. Finally, Bank of New York Mellon Corp increased its stake in Loxo Oncology by 41.8% in the first quarter. Bank of New York Mellon Corp now owns 102,442 shares of the biopharmaceutical company’s stock valued at $4,310,000 after buying an additional 30,210 shares during the period.

Loxo Oncology, Inc. (LOXO) traded up 0.94% on Wednesday, hitting $78.49. The stock had a trading volume of 71,589 shares. The firm’s market cap is $2.34 billion. The company has a 50-day moving average price of $73.71 and a 200 day moving average price of $57.32. Loxo Oncology, Inc. has a 52-week low of $17.14 and a 52-week high of $83.12.

Loxo Oncology (NASDAQ:LOXO) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.99) by $0.15. During the same quarter in the prior year, the business posted ($0.77) EPS. Equities analysts forecast that Loxo Oncology, Inc. will post ($4.54) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This story was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/08/30/bank-of-america-corp-de-has-344000-stake-in-loxo-oncology-inc-loxo.html.

LOXO has been the topic of several analyst reports. Zacks Investment Research raised Loxo Oncology from a “hold” rating to a “buy” rating and set a $52.00 target price on the stock in a report on Wednesday, May 3rd. Citigroup Inc. raised Loxo Oncology from a “neutral” rating to a “buy” rating and set a $86.00 target price on the stock in a report on Monday, June 5th. Stifel Nicolaus boosted their target price on Loxo Oncology from $52.00 to $71.00 and gave the stock a “buy” rating in a report on Monday, June 5th. Cowen and Company reissued an “outperform” rating on shares of Loxo Oncology in a report on Monday, June 5th. Finally, BTIG Research reissued a “buy” rating and issued a $75.00 target price on shares of Loxo Oncology in a report on Tuesday, June 6th. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $70.73.

In other Loxo Oncology news, insider Naarden Jacob Van sold 1,541 shares of the company’s stock in a transaction on Monday, August 14th. The shares were sold at an average price of $73.73, for a total value of $113,617.93. Following the completion of the transaction, the insider now owns 1,541 shares in the company, valued at $113,617.93. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Jennifer Burstein sold 1,700 shares of the company’s stock in a transaction on Monday, August 14th. The shares were sold at an average price of $73.73, for a total transaction of $125,341.00. Following the completion of the transaction, the vice president now owns 1,700 shares of the company’s stock, valued at approximately $125,341. The disclosure for this sale can be found here. Insiders sold 46,073 shares of company stock valued at $3,397,662 in the last 90 days. 27.80% of the stock is currently owned by insiders.

Loxo Oncology Company Profile

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Institutional Ownership by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Stock Ratings for Loxo Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology Inc. and related stocks with our FREE daily email newsletter.